Halozyme Inks $2B+ in ENHANZE Licensing Deals with BMS, Roche
Halozyme Therapeutics today disclosed collaboration and licensing agreements for its ENHANZE® drug-delivery technology with Bristol-Myers Squibb (BMS) and Roche—deals totaling up to a combined $2 billion-plus.…
Read guide →